Equities

Valbiotis SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Valbiotis SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.12
  • Today's Change0.026 / 2.38%
  • Shares traded242.55k
  • 1 Year change-17.37%
  • Beta0.0521
Data delayed at least 15 minutes, as of Feb 09 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

  • Revenue in EUR (TTM)472.00k
  • Net income in EUR-11.12m
  • Incorporated2014
  • Employees44.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Plant Advanced Technologies PAT SA941.74k318.01k9.42m16.0030.261.0010.6710.010.27760.27760.83778.38------58,858.75---1.51---1.96144.97128.3233.77-13.360.3156--0.2867--14.6110.441,081.17------
Oncodesign Precision Medicine Opm SA207.25k6.27m10.21m13.001.600.9631.5649.260.34570.34570.01140.57320.0119--0.263411,513.8936.11--54.21--6,372.89--3,026.21--0.92620.810.3859---80.69--10.89------
Predilife SA728.07k-3.80m12.58m27.00------17.28-0.9936-0.99360.1905-1.260.3919--3.6336,421.71-204.34-93.24---132.8098.1089.32-521.48-1,377.00---19.99----55.2084.82-0.9621---24.35--
Nfl Biosciences SAS0.00-3.15m14.57m4.00--4.26-----0.2779-0.27790.000.26990.00----0.00-66.86-75.08-91.01-121.22------------0.0088------44.44------
Poxel SA7.66m-13.66m16.48m5.00------2.15-0.2594-0.25940.1443-1.141.45--8.901,276,167.00-258.08-69.11---133.5152.0280.83-178.45-475.98---0.1862----234.98-24.2247.83------
Gensight Biologics SA194.00k-15.12m18.33m13.00------94.50-0.1293-0.12930.0016-0.2450.0174--10.7816,166.67-135.38-81.19---203.71-----7,793.81-868.76--------18.3916.4746.60---57.94--
Valbiotis SA472.00k-11.12m25.93m44.00--2.20--54.93-0.6994-0.69940.02970.49670.02061.574.8910,727.27-48.58-33.12-61.97-47.09-603.8119.74-2,354.87-464.772.93-74.380.3129---96.3013.97-36.06---2.02--
Novacyt SA22.00m-31.97m28.01m234.00--0.5948--1.27-0.4529-0.4960.31180.66670.23542.345.2794,014.46-34.205.59-39.097.2963.3566.74-145.329.834.59-7.230.2114--84.8211.35-60.50--55.60--
Theranexus SA0.00-2.94m29.52m10.00---------0.3641-0.36410.00-0.19230.00----0.00-66.82-44.47-148.89-50.85-----------37.712.90------74.15---56.53--
genOway SA20.95m1.29m31.63m148.0016.741.187.821.510.14870.14872.422.120.5940.87973.69146,514.103.652.104.722.9194.9194.806.143.762.21--0.4407--10.0418.4616.79--15.88--
Fermentalg SA12.78m-11.54m37.82m63.00--1.33--2.96-0.1242-0.12420.13530.31560.24727.913.29199,734.40-17.09-18.10-21.17-20.5920.9425.51-69.14-147.661.83--0.2368--183.3243.528.99---4.91--
Eurofins Cerep SA40.46m7.15m81.21m207.0011.351.138.492.011,418.431,418.438,027.2414,234.140.49551.614.75195,445.808.7613.1210.2315.9085.6780.0217.6820.226.53--0.0046---8.205.46-6.3410.36----
Data as of Feb 09 2026. Currency figures normalised to Valbiotis SA's reporting currency: Euro EUR

Institutional shareholders

6.92%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Jan 20261.01m4.26%
Friedland Gestion SASas of 30 Sep 2025438.72k1.85%
Pure Capital SAas of 30 Jun 2025158.84k0.67%
MW Gestion SAas of 30 Jun 202533.63k0.14%
Itavera Asset Management SASas of 31 Dec 20240.000.00%
Amiral Gestion SAas of 31 Dec 20240.000.00%
More ▼
Data from 31 Dec 2024 - 01 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.